Protein Kinase C-delta Inhibitor Peptide Formulation using Gold Nanoparticles

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Pharmacology

Background:

• Protein kinase C-delta inhibitor (PKCδi) shows potential for preventing ischemia-reperfusion injury.
• Traditional delivery via TAT peptide has limitations due to non-specific biological activities.
• Gold nanoparticles (GNPs) are explored as safe and effective drug delivery carriers.

Purpose of the Study:

• To develop a novel GNP/peptide hybrid system for intracellular delivery of PKCδi.
• To formulate and characterize GNP-conjugated PKCδi (GNP/PKCi).
• To evaluate the potential of GNP/PKCi in preventing organ injury.

Main Methods:

• Surface modification of GNPs using a specific ratio of two short peptides (P2 and P4).
• Conjugation of PKCδi to the modified GNPs.
• Assessment of GNP/PKCi stability in various aqueous solutions (distilled water, NaCl, PBS with serum).
• Physicochemical characterization of the formulated GNP/PKCi.

Main Results:

• GNP/PKCi formulations demonstrated stability in diverse physiological solutions.
• Previous studies showed intravenous administration of GNP-PKCi prevented lung ischemia-reperfusion injury.
• The study provides a protocol for formulating GNP/PKCi and assessing its properties.

Conclusions:

• GNP/peptide hybrid systems represent a promising intracellular drug delivery technology.
• This approach offers a safer alternative to TAT-mediated delivery for PKCδi.
• The developed formulation and characterization methods can be applied to other peptide-based drugs for in vivo applications.